valu usd unless otherwis note
play dart dark nearli hit
view report result better expect
provid reason optimist busi continu face
near term challeng remain sidelin get better
visibl optim translat oper perform
result better expect store perform
divest store bit wors model mean balanc
busi deliv better result deliv adjust ebitda
y/i ahead estim
street revenu earn remain store
better model compani averag howev
mani compani key perform metric continu trend
neg store rx fell pharmaci sale fell front
end store sale rel bright spot outperform
rx comp comfort
aim bull manag struck optimist tone
call cite mani thing break way
walgreen deal product discuss
reimburs rate better region footprint
foil walgreen market envis
pbm forecast growth live exit
commerci attrit envis execut excit
sell season could pois win busi due cvs-aet
deal cost save plan place could
procur upsid switch gener buy wbad
adjust estim adjust number reflect
pro forma busi exclud store sold
revenu estim adjust ebitda estim
lower estim reflect cautiou
forecast retail segment partial off-set stronger medicar part
enrol pbm segment adjust ebitda estim
maintain sector perform maintain sector perform rate
share price target price target base ev/
ebitda multipl appli ebitda estim million
ev/ebitda multipl discount larger competitor
price prior trade day market close estimate unless otherwis note
rite aid third-largest pharmaci chain unit
state compani current agreement sell
store expect close
end time oper
store retail pharmaci segment also
includ health dialog rediclin busi
pharmaci servic segment consist compani pbm
expect asset sale
complet view transact posit stabil
improv compani competit
posit market concentr certain
region believ super region strategi
allevi current reimburs pressur pbm
expect better growth trend envis pbm
busi within believ segment still
challeng envis pbm significantli less
scale compar three larg pbm result would
difficulti match price competitor
offer client
complet asset sale
drug price trend purchas perform
bloomberg capit market estim upside/downside/target
base case price target base ev/
ebitda multipl appli ebitda estim
million ev/ebitda multipl discount larger
competitor
upsid scenario price base
ev/ebitda multipl appli ebitda ahead
base case forecast multipl approxim
line multipl
downsid scenario price base
ev/ebitda multipl appli ebitda
base case forecast multipl materi discount
competitor reflect scenario deterior
ebitda warrant multipl well competitor
price target share base ev/ebitda appli
adjust ebitda estim million multipl repres discount trade
rang larger retail pharmaci competitor believ warrant given
rel lack scale disadvantag competit posit price target support
risk rate price target
risk sector perform rate unabl complet asset sale
could pressur share oper result leverag ratio
would like concern equiti debt investor follow transact walgreen rite
aid much smaller pharmaci competitor could face signific reimburs
pressur rite aid could lose market share competitor abil
anchor pharmaci chain nation prefer pharmaci network pbm busi
could pressur larger nation pbm offer integr busi model includ
integr pharmaci model integr medic care model gener trend drug
price also risk reimburs profit could pressur
lower gener price slower brand price growth
third-largest pharmaci chain unit state oper store
june compani enter asset purchas agreement walgreen
boot allianc sell store fail get regulatori approv earlier
agreement acquir asset sale rite aid fifth-largest
pharmaci revenu
million
cost expens
good sold
cog revenu
sell gener administr expens
sg revenu
leas termin impair charg
loss gain debt retir net
loss sale asset net
depreci amort
incom loss incom tax
numer earn loss per share
accret redeem prefer stock
incom loss attribut common stockhold basic
add back interest convert note
incom loss attribut common stockhold dilut
amort envis intang asset
merger acquisition-rel cost
adjust loss incom incom tax
outstand option restrict share
compani report capit market estim
